Y-mAbs Therapeutics
YMAB
YMAB was delisted on the 15th of September, 2025.
45 hedge funds and large institutions have $222M invested in Y-mAbs Therapeutics in 2019 Q1 according to their latest regulatory filings, with 7 funds opening new positions, 13 increasing their positions, 14 reducing their positions, and 4 closing their positions.
75% more first-time investments, than exits
New positions opened: 7 | Existing positions closed: 4
27% more capital invested
Capital invested by funds: $176M → $222M (+$46.6M)
7% more funds holding
Funds holding: 42 → 45 (+3)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.6% less ownership
Funds ownership: 25.41% → 24.8% (-0.6%)
7% less repeat investments, than reductions
Existing positions increased: 13 | Existing positions reduced: 14
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$11.4M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$5.51M |
| 3 |
AllianceBernstein
Nashville,
Tennessee
|
+$2.36M |
| 4 |
BlackRock
New York
|
+$600K |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$599K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SCM
Scopia Capital Management
New York
|
-$14.7M |
| 2 |
ACA
Avoro Capital Advisors
New York
|
-$6.3M |
| 3 |
Millennium Management
New York
|
-$2.23M |
| 4 |
AG
Artal Group
Luxembourg
|
-$1.02M |
| 5 |
MWNA
Marshall Wace North America
New York
|
-$844K |
YMAB Hedge Fund Activity: Q1 2019 in Review
45 of the 4,633 institutional investors tracked by Wall St. Rank reported a position in Y-mAbs Therapeutics (YMAB) for Q1 2019, worth a combined $222M — up 27% from $176M a quarter earlier.
Buyers outnumbered sellers: 7 funds opened new YMAB positions and 4 closed out — a net gain of 3 holders — while 13 added to existing stakes and 14 trimmed.
The largest buyer was Cormorant Asset Management, adding an estimated $11.4M. The largest seller was Scopia Capital Management, cutting an estimated $14.7M.
- 45 institutional investors held Y-mAbs Therapeutics (YMAB) as of Q1 2019, up from 42 in Q4 2018.
- Funds reported $222M of Y-mAbs Therapeutics stock for Q1 2019, up 27% quarter-over-quarter.
- 7 funds opened new Y-mAbs Therapeutics positions in Q1 2019 and 4 closed out, a net change of +3 holders.
- The largest Y-mAbs Therapeutics buyer in Q1 2019 was Cormorant Asset Management, an estimated $11.4M added.
- The largest Y-mAbs Therapeutics seller in Q1 2019 was Scopia Capital Management, an estimated $14.7M sold.
Based on aggregated 13F filings for Q1 2019.